N/A N=13 Effect of Cola on Urinary Stone Risk Factors
Kidney Stone
Primary: The Plasma and Urine Parameters — 6800; 6800; 3700; 3700 mg per dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Hyperoxaluria · Nephrolithiasis
Primary: Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion — -13.92 mg/day
Phase 2 N=20 Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
Cystinuria · Nephrolithiasis, Calcium Oxalate
Primary: 24 Hour Urine Supersaturation of Calcium Oxalate (CaOx) — 1.83; 1.83; 1.87; 1.78 KJoules/mol — p=0.32
N/A N=104 Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones
Urolithiasis · Urinary Lithiasis · Kidney Calculi
Primary: Stone Clearance — 76 participants
Phase 2 N=13 Treatment for Calcium Phosphate Kidney Stone Disease
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Phase 2 N=10 The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
N/A N=58 Obesity and Endogenous Oxalate Synthesis
Obesity
Primary: Urinary Oxalate Excretion — 24 mg/day
N/A N=1,658 Prevention of Urinary Stones With Hydration
Urinary Stones
Primary: Number of Participants With a Symptomatic Stone Event — 154; 165 Participants
Phase 4 N=512 Tamsulosin for Urolithiasis in the Emergency Dept
Ureterolithiases
Primary: Proportion of Patients Passing Their Stone Within 28 Days by Self Report — 128; 113 Participants
Phase 3 N=416 Hydrochlorothiazide for Kidney Stone Recurrence Prevention
Nephrolithiasis
Primary: Number of Participants With Stone Recurrences — 60; 62; 61; 49 Participants
Phase 2 N=99 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
Hyperuricosuria · Kidney Stones
Primary: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion — -58.6; -36.4; -12.7 percent change — p=<0.001
Phase 4 N=29 Vitamin D Repletion in Stone Formers With Hypercalciuria
Nephrolithiasis · Urolithiasis · Idiopathic Hypercalciuria
Primary: Change in 24 Hour Urine Calcium — 2 mg/day
N/A N=108 Trial Assessing Renal Damage During Ureteroscopy
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml
N/A N=234 Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy
Nephrolithiasis
Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01
N/A N=270 Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Kidney Stones
Primary: Stone Clearance Time in mm2/Min — 24.0; 28.9; 32.3 mm^2/min
N/A N=100 Medical Expulsive Therapy of Single Distal Ureteral Stones
Ureteral Calculi
Primary: Number of Participants With Stone Expulsion — 39; 40 Participants
N/A N=53 Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis
Kidney Stone
Primary: Time of Stone Passage — 68.8; 19.0 hours
N/A N=101 Comparison of Laser Lithotripsy With and Without Steerable Ureteroscopic Renal Evacuation (SURE)
Kidney Stone · Renal Stone · Urolithiasis
Primary: Stone Free Rate (SFR) - Zero Fragments — 48; 49 % subjects
Phase 2 N=239 Study of Silodosin to Facilitate Passage of Urinary Stones
Ureteral Calculi · Kidney Stones · Urolithiasis
Primary: Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures…
Phase 4 N=2,776 Study of Tomography of Nephrolithiasis Evaluation
Urolithiasis
Primary: High Risk Diagnosis With Complication — 6; 3; 2 participants
Phase 2 N=33 Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
Ureteral Obstruction · Flank Pain
Primary: Spontaneous Stone Passage Using Fisher's Exact Test — 8; 5 Participants
N/A N=30 Evaluation of a Nonopioid Recovery Pathway Following Surgery for Kidney Stones
Nephrolithiasis
Primary: Protocol Feasibility — 14; 10 Participants
Phase 4 N=17 Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy
Renal Calculus · Kidney Stones
Primary: Pain 'Right Now' — 1.0; 0.9 units on a scale
Phase 2 N=63 Contrast-enhanced Ultrasound of the Kidney
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
N/A N=70 Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Kidney Stones
Primary: Kidney Stone Clearance Rate — 61.9; 75.8 mm^2/min
N/A N=127 The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
Kidney Stones · Ureteral Stones
Primary: Stone Passage — 18; 21 participants
Phase 2 N=50 Lipoic Acid Supplement for Cystine Stone
Cystinuria
Primary: Cystine Stone Recurrence — 16; 23 Participants
Phase 2 N=25 Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Chronic Kidney Diseases · Cystic Kidney Disease
Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants
Phase 4 N=86 A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
Nephrolithiasis · Urinary Tract Infections
Primary: Number of Participants That Developed Sepsis After Surgery — 5; 6 Participants
N/A N=171 A Comparison of Ureteroscopic Treatment of Nephrolithiasis With and Without Moses Technology
Nephrolithiasis
Primary: Operative Time — 36; 37 minutes